<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114618</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOTHROMB12-01</org_study_id>
    <nct_id>NCT03114618</nct_id>
  </id_info>
  <brief_title>A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient</brief_title>
  <acronym>ONCOTHROMB</acronym>
  <official_title>Genomic Predictors Indicating the Risk of Venous Thromboembolic Disease in Cancer Patients Treated in Outpatient Clinics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres muñoz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio de Oncología Médica. HGU Gregorio Marañón. Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unitat de Genòmica de Malalties Complexes. Institut d’Investigació Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complexo Hospitalario de Ourense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complejo Universitario Torrecárdenas, Almería</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gendiag</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferrer inCode, S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unitat d’Hemostasia i Trombosi. Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Trombosis y Hemostasia (SETH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major
      causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients
      are receiving chemotherapy. Current risk scores for predicting cancer-associated VTE in
      ambulatory patients had low/moderate discrimination and clinical sensitivity. These models
      use clinical and biochemical parameters of the patient.

      In the development of VTE genetics play a relevant role. The product Thrombo inCode (TiC)
      assess VTE risk prediction by using a combination of a genetic risk score (GRS) and clinical
      parameters from the patient. The investigators hypothesized that the GRS included in TiC
      combined with clinical parameter some of them associated with cancer could be better
      predicted by TiC than by current risk scores (Khorana score).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The working hypothesis of this study establishes that the risk of cancer patients suffering a
      thromboembolic event is conditioned by individual genomic factors. The genes to be analyzed
      have clearly demonstrated their relationship with thromboembolic disease in other clinical
      contexts. This study is considered the initiation of a field of research in genomic risk
      markers indicating a risk of thrombosis in cancer patients. The ultimate goal of the study is
      to establish a clinic-genomic score for selecting patients with a high risk of suffering
      thrombotic events who can benefit from guided thromboprophylaxis. Its secondary goal is to
      prevent the adverse effects of ineffective therapies in other patients (low-risk patients not
      requiring an anti-thrombotic prophylaxis).

      The aim is to demonstrate the link between the clinic-genetic profile and the risk of
      suffering thromboembolic events in the group of cancer patients. The working hypothesis
      establishes that cancer patients who develop thrombotic events will have a higher score for
      the thrombosis risk clinic-genetic profile than cancer patients not developing thromboembolic
      events. The second aim is to analyse whether the thrombosis clinic-genetic risk score
      improves the detection of patients at risk of suffering a thromboembolic event compared to
      the Khorana predictive model routinely used (Khorana score).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism events</measure>
    <time_frame>During the 18 months of follow up</time_frame>
    <description>The development of venous thromboembolism will be registered</description>
  </primary_outcome>
  <enrollment type="Actual">406</enrollment>
  <condition>Venous Thromboembolism (Deep Vein Thrombosis or Pulmonary Embolism), Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include patients diagnosed with colorectal, esophago-gastric, pancreas or
        lung cancer who have not previously been treated with chemotherapy or chemotherapy and
        radiation therapy and are candidate for chemotherapy in outpatient setting
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age.

          -  Patients treated in outpatient clinics with a documented histological or cytological
             diagnosis for non-microcytic lung, colorectal, pancreatic or esophago-gastric cancer
             at an advanced stage, locally advanced or localized not previously treated with
             systemic chemotherapy and/or radiation therapy who are candidate for chemotherapy in
             outpatient setting.

          -  Performance status 0-2.

          -  Patients signing the study informed consent form.

        Exclusion Criteria:

          -  Life expectancy of less than 3 months.

          -  Patients undergoing anti-coagulant treatment before the cancer diagnosis, for reasons
             other than a venous thromboembolic event.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés J. Muñoz Martín, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopsital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almeria</city>
        <state>Almería</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Soria JM, Morange PE, Vila J, Souto JC, Moyano M, Trégouët DA, Mateo J, Saut N, Salas E, Elosua R. Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc. 2014 Oct 23;3(5):e001060. doi: 10.1161/JAHA.114.001060.</citation>
    <PMID>25341889</PMID>
  </results_reference>
  <results_reference>
    <citation>Rubio-Terrés C, Soria JM, Morange PE, Souto JC, Suchon P, Mateo J, Saut N, Rubio-Rodríguez D, Sala J, Gracia A, Pich S, Salas E. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism. Appl Health Econ Health Policy. 2015 Apr;13(2):233-42. doi: 10.1007/s40258-015-0153-x.</citation>
    <PMID>25652150</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Andres muñoz</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

